TIMELINE 2024 December 17, 2024 Positive Interim Phase 2 Data of Elraglusib in pancreatic cancer August 14, 2024 Initial Public Offering August 1, 2024 FDA Orphan Drug Designation for Elraglusib February 9, 2024 The Last Patient’s First Dose of Elraglusib in pancreatic cancer January 2024 Completion of Enrollment in Phase 2 clinical study in […]
ABOUT US Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41). Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such
PRIVACY NOTICE Last updated and effective as of December 20, 2023. This Privacy Notice explains the practices that Actuate Therapeutics, Inc. (“Actuate”, “we”, “us”, “our”) follows in connection with the personal data that we collect through this website, when you contact us directly and through our research. We may change this Privacy Notice at any
Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate inCombination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PANCREATIC CANCER Read More »
CHICAGO, IL and FORT WORTH, TX, January 15, 2018 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical study of 9-ING-41, Actuate’s lead agent – a proprietary GSK-3β inhibitor. This initial IND
ACTUATE THERAPEUTICS SUBMITS IND APPLICATION FOR TREATMENT OF REFRACTORY CANCERS Read More »
